Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

261. Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer

Kyushu Cancer Center, Fukuoka, Japan. 11 Department of General Thoracic Surgery, Breast and Endocrinological Surgery, Okayama University, Okayama, Japan. 12 Department of Thoracic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan. 13 Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan. 14 Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. 15 Department (...) Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History

2020 EvidenceUpdates

262. Variation in the Association between Antineoplastic Therapies and Venous Thromboembolism in Patients with Active Cancer

Variation in the Association between Antineoplastic Therapies and Venous Thromboembolism in Patients with Active Cancer Variation in the Association Between Antineoplastic Therapies and Venous Thromboembolism in Patients With Active Cancer - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National (...) : Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Thromb Haemost Actions . 2020 May;120(5):847-856. doi: 10.1055/s-0040-1709527. Epub 2020 May 5. Variation in the Association Between Antineoplastic Therapies and Venous Thromboembolism in Patients With Active Cancer , , , , , , , , , Affiliations Expand Affiliations 1 Vascular and Emergency Medicine and Stroke Unit, University of Perugia, Perugia, Perugia, Italy. 2 Division of Cardiology

2020 EvidenceUpdates

263. Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phas

a predefined stopping criterion for inferiority. Conclusions: The reduced frequency schedule was inferior to the standard schedule regarding the time to first recurrence. Further recruitment of patients was stopped immediately to avoid harm in the reduced frequency BCG arm. Patient summary: After surgical removal of the tumour, patients with high-grade non-muscle-invasive bladder cancer are treated with bacillus Calmette-Guérin to prevent recurrence and progression. This is associated with significant side (...) effects. We report the results of a clinical trial showing a reduction in the number of instillations (from 15 to nine in total) being inferior to the standard protocol. From today's perspective, complete tumour resection and a standard number of instillations remain the standard of care. Keywords: Bacillus Calmette-Guérin; Instillation therapy; Non–muscle-invasive bladder cancer; Reduced frequency. Copyright © 2020. Published by Elsevier B.V. Similar articles Järvinen R, Marttila T, Kaasinen E

2020 EvidenceUpdates

264. Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study Full Text available with Trip Pro

survival (rPFS) versus ADT alone. Objective: To evaluate patient-reported outcomes (PROs) to week 73. Design, setting, and participants: ARCHES ( ) was a randomised, double-blind, placebo-controlled, phase 3 study in mHSPC patients. Intervention: Enzalutamide (160 mg/day) plus ADT or placebo plus ADT. Outcome measurements and statistical analysis: PROs were assessed at baseline, week 13, and every 12 wk until disease progression using the European Organisation for Research and Treatment of Cancer (...) for confirmed deterioration for pain outcomes). Enzalutamide delays deterioration in several HRQoL subscales and pain severity in high-volume disease. Conclusions: Enzalutamide plus ADT enables men with mHSPC to maintain high-functioning HRQoL and low symptom burden. Patient summary: This study examined the effect on health-related quality of life and pain of adding enzalutamide or placebo to androgen deprivation therapy for patients with metastatic hormone-sensitive prostate cancer. Addition

2020 EvidenceUpdates

265. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines

of MMIBC. The recommendations are based on the current literature (until the end of 2019), with emphasis on high-level data from randomised clinical trials and meta-analyses and on the findings of an international consensus meeting. Surgical removal of the bladder and bladder preservation are discussed, as well as the use of chemotherapy and immunotherapy in localised and metastatic disease. Keywords: Bladder cancer; Cystectomy; Diagnosis; European Association of Urology; Follow-up; Guidelines (...) European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health

2020 EvidenceUpdates

266. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. 6 N N Petrov Research Institute of Oncology, St Petersburg, Russia. 7 12 de Octubre University Hospital, Medical Oncology Department, Madrid, Spain. 8 National Center for Tumor Diseases, University Hospital, German Cancer Research Center, Heidelberg, Germany. 9 Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. 10 F Hoffmann-La Roche, Basel, Switzerland. 11 Roche Products, Welwyn Garden City, UK. 12 (...) , Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. 6 N N Petrov Research Institute of Oncology, St Petersburg, Russia. 7 12 de Octubre University Hospital, Medical Oncology Department, Madrid, Spain. 8 National Center for Tumor Diseases, University Hospital, German Cancer Research Center, Heidelberg, Germany. 9 Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. 10 F Hoffmann-La Roche, Basel, Switzerland. 11 Roche Products, Welwyn Garden City, UK. 12

2020 EvidenceUpdates

267. The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Full Text available with Trip Pro

The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients With Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label (...) Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients With Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 The Institute of Cancer Research and Royal Marsden Hospital, London, UK. Electronic address: david.dearnaley@icr.ac.uk. 2 Urology San Antonio, San Antonio, TX, USA. 3 21st Century

2020 EvidenceUpdates

268. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, rand Full Text available with Trip Pro

: TRIBE2 was an open-label, phase 3, randomised study of patients aged 18-75 years with an Eastern Cooperative Oncology Group (ECOG) performance status of 2, with unresectable, previously untreated metastatic colorectal cancer, recruited from 58 Italian oncology units. Patients were stratified according to centre, ECOG performance status, primary tumour location, and previous adjuvant chemotherapy. A randomisation system incorporating a minimisation algorithm was used to randomly assign patients (1:1 (...) , and one sepsis). Interpretation: Upfront FOLFOXIRI plus bevacizumab followed by the reintroduction of the same regimen after disease progression seems to be a preferable therapeutic strategy to sequential administration of chemotherapy doublets, in combination with bevacizumab, for patients with metastatic colorectal cancer selected according to the study criteria. Funding: The GONO Cooperative Group, the ARCO Foundation, and F Hoffmann-La Roche. Copyright © 2020 Elsevier Ltd. All rights reserved

2020 EvidenceUpdates

269. Effectiveness of auricular point therapy for cancer-related fatigue: A systematic review and meta-analysis

Effectiveness of auricular point therapy for cancer-related fatigue: A systematic review and meta-analysis Effectiveness of Auricular Point Therapy for Cancer-Related Fatigue: A Systematic Review and Meta-Analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National (...) RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Review J Adv Nurs Actions . 2020 May 19. doi: 10.1111/jan.14375. Online ahead of print. Effectiveness of Auricular Point Therapy for Cancer-Related Fatigue: A Systematic Review and Meta-Analysis , , , , , , , Affiliations Expand Affiliations 1 School of Nursing, Fujian University of Traditional Chinese Medicine, Fuzhou, China. 2 School of Nursing, The Hong Kong Polytechnic University, Hong Kong, China. 3 Fujian Provincial

2020 EvidenceUpdates

270. Management of Cancer Cachexia: ASCO Guideline

Management of Cancer Cachexia: ASCO Guideline Management of Cancer Cachexia: ASCO Guideline - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National Center for Biotechnology Information Show account info Close Account Logged in as: username (My NCBI) (My Bibliography (...) ;JCO2000611. doi: 10.1200/JCO.20.00611. Online ahead of print. Management of Cancer Cachexia: ASCO Guideline , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Massachusetts General Hospital Cancer Center, Boston, MA. 2 American Society of Clinical Oncology, Alexandria, VA. 3 University of Alberta, Edmonton, Alberta, Canada. 4 MD Anderson Cancer Center, Houston, TX. 5 Virginia Commonwealth University, Richmond, VA. 6 Cambia Health Solutions, Portland, OR. 7 Edinburgh Oncology Centre

2020 EvidenceUpdates

271. CIRSE Standards of Practice on Thermal Ablation of Liver Tumours

of liver tumours, including radiofrequency, microwave and cryoablation techniques. This is a preview of subscription content, to check access. Access options References 1. Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom, Charboneau JW, et al. International Working Group on Image-Guided Tumor Ablation, Interventional Oncology Sans Frontières Expert Panel, Technology Assessment Committee of the Society of Interventional Radiology, Standard of Practice Committee of the Cardiovascular and Interventional (...) Radiological Society of Europe, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria—a 10-year update. J Vasc Interv Radiol. 2014;25(11):1691–705. 2. Wang X, Sofocleous CT, Erinjeri JP, Petre EN, Gonen M, Do KG, et al. Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases. Cardiovasc Interv Radiol. 2013;36(1):166–75. 3. Kim YS, Lee WJ, Rhim H, Lim HK, Choi D, Lee JY. The minimal ablative margin

2020 Cardiovascular and Interventional Radiological Society of Europe

272. Shared follow-up care for women with low-risk endometrial cancer: A guide for General Practitioners

requiring further investigation and management. Addressing co-morbidities including obesity-related issues, hypertension and diabetes is important with evidence suggesting that, overall, cardiovascular disease is the leading cause of death among endometrial cancer patients. 3 Interventions and investigations aimed at addressing risk factors for these diseases may have the greatest potential to improve outcomes for women diagnosed with low-risk endometrial cancer. GPs can provide whole person care (...) below. Identify, monitor and manage newly emerging or ongoing co-morbidities as required, including obesity, diabetes and cardiovascular disease Actively promote secondary prevention strategies and encourage realistic goal-setting (including maintaining a healthy body weight, regular exercise, quitting smoking and limiting alcohol intake) Women who require management of menopausal symptoms after treatment of endometrial cancer should be managed in consultation with the treating gynaecological cancer

2020 Cancer Australia

273. Management of Cancer Cachexia

Management of Cancer Cachexia Supportive Care and Treatment Related Issues | ASCO Search form Search ASCO Family of Sites ASCOconnection.org features blogs from members, the online version of the membership magazine, a discussion area, working groups, and links to the Membership Directory, Career Center, and Volunteer Portal. ASCO Daily News is the official conference reporter for ASCO meetings and symposia, providing high-quality, unbiased research summaries and oncology news to members (...) and oncology health care providers. ASCO’s growing roster of cutting-edge journals serves readers as the most credible, authoritative, peer-reviewed resources for significant clinical oncology research and research that informs the delivery of efficient, high-quality cancer care across the globe. ASCO Practice Central helps oncology professionals navigate a complicated and ever-changing practice environment—while providing high-quality patient care. ASCO eLearning serves as a comprehensive online learning

2020 American Society of Clinical Oncology Guidelines

274. Larotrectinib for treating NTRK fusion-positive solid tumours

live after their disease gets worse. Collecting more data would help to address some of the uncertainties in the clinical evidence. Larotrectinib has the potential to be a cost-effective use of NHS resources at its current price so it is recommended through the Cancer Drugs Fund while these data are collected. Larotrectinib for treating NTRK fusion-positive solid tumours (TA630) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice (...) is needed characterisation is needed 3.2 NTRK gene fusions occur rarely (less than 1%) in common tumours such as lung, colorectal and breast cancers. Some rare tumour types have more than 90% NTRK fusion prevalence (for example, mammary analogue secretory carcinoma and infantile fibrosarcoma). There are many tumour types with known NTRK gene fusions and all solid tumour types are included in larotrectinib's marketing authorisation. NTRK fusions can involve portions of the NTRK1, NTRK2 and NTRK3 genes

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

275. Capmatinib (Tabrecta) - To treat patients with non small cell lung cancer

Capmatinib (Tabrecta) - To treat patients with non small cell lung cancer Drug Approval Package: TABRECTA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: TABRECTA Company: Novartis Pharmaceuticals Corporation Application Number: 213591 Approval Date: 05/06/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF

2020 FDA - Drug Approval Package

276. Tucatinib (Tukysa) - To treat advanced unresectable or metastatic HER2-positive breast cancer

Tucatinib (Tukysa) - To treat advanced unresectable or metastatic HER2-positive breast cancer Drug Approval Package: TUKYSA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: TUKYSA Company: Seattle Genetics, Inc. Application Number: 213411 Approval Date: 04/17/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF

2020 FDA - Drug Approval Package

277. Sacituzumab govitecan-hziy (Trodelvy) - To treat adult patients with metastatic triple-negative breast cancer

Sacituzumab govitecan-hziy (Trodelvy) - To treat adult patients with metastatic triple-negative breast cancer Drug Approval Package: TRODELVY U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: TRODELVY Company: Immunomedics, Inc Application Number: 761115 Approval Date: 04/22/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application

2020 FDA - Drug Approval Package

278. Thoracoscopy and talc poudrage compared with intercostal drainage and talc slurry infusion to manage malignant pleural effusion: the TAPPS RCT Full Text available with Trip Pro

Thoracoscopy and talc poudrage compared with intercostal drainage and talc slurry infusion to manage malignant pleural effusion: the TAPPS RCT Thoracoscopy and talc poudrage compared with intercostal drainage and talc slurry infusion to manage malignant pleural effusion: the TAPPS RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from (...) the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} This trial found no evidence of any difference between talc poudrage at thorocoscopy and bedside chest drain and talc slurry for the management of malignant pleural effusion. {{author}} {{($index , , , , & . Rahul Bhatnagar 1 , Ramon Luengo-Fernandez 2 , Brennan C Kahan 3 , Najib M Rahman 4 , Robert F Miller 5 , Nick A Maskell 1

2020 NIHR HTA programme

279. Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer

nodes after neoadjuvant taxane-based and HER2-targeted therapy. It is recommended only if the company provides trastuzumab emtansine according to the commercial arrangement. Why the committee made these recommendations Why the committee made these recommendations Neoadjuvant therapy aims to reduce the size of the tumour before surgery. It sometimes shrinks completely, but people may still have cancer remaining when they have their surgery (residual invasive disease). The cancer may have spread (...) to eradicate or reduce tumour size before surgery. NICE recommends pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer, with trastuzumab and chemotherapy, for locally advanced, inflammatory or early breast cancer at high risk of recurrence. The patient expert explained that when residual disease is found during surgery this is a disappointing outcome, and preventing the cancer returning is very important to patients. After surgery, adjuvant treatment is used to reduce the risk

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

280. Radiation Therapy for Cervical Cancer Full Text available with Trip Pro

of interest). The scope is limited to curative management of invasive carcinomas of the uterine cervix, which include squamous cell carcinomas and adenocarcinomas, and does not include rare histologies, noninvasive disease or palliative treatment. It focuses on management of cervical cancer with RT and its indications, techniques, and outcomes. It additionally covers other therapies that modify the efficacy of RT when used concurrently or in sequence (eg, chemotherapy or surgery). Key Questions (...) no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol Oncol. 1999; 73 : 177-183 Occult cervical cancer after total hysterectomy For women who are found to have an occult invasive cervical cancer after total hysterectomy (either for benign disease or uterine cancer), further treatment is needed for stages greater than or equal to IA2 because a radical hysterectomy with lymph node

2020 American Society for Radiation Oncology